Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (241-250 of 313) with videos related to

Pageof 32
Sort By:
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Arrhythmia and Electrophysiology|February 21, 2020
Initial Precipitants and Recurrence of Atrial FibrillationElizabeth Y Wang, Olivia L Hulme, Shaan Khurshid, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryMichael W Cullen, Sunghee Kim, Jonathan P Piccini, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Pageof 32

Showing results (241-250 of 313) with videos related to

Sort By:
Pageof 32
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Arrhythmia and Electrophysiology|February 21, 2020
Initial Precipitants and Recurrence of Atrial FibrillationElizabeth Y Wang, Olivia L Hulme, Shaan Khurshid, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryMichael W Cullen, Sunghee Kim, Jonathan P Piccini, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Pageof 32